Literature DB >> 26605288

National consensus in China on diagnosis and treatment of patients with advanced breast cancer.

Binghe Xu1, Xichun Hu1, Zefei Jiang1, Huiping Li1, Jiayi Chen1, Shude Cui1, Qing Li1, Ning Liao1, Donggeng Liu1, Jian Liu1, Jinsong Lu1, Kunwei Shen1, Tao Sun1, Yuee Teng1, Zhongsheng Tong1, Shulian Wang1, Xiang Wang1, Xiaojia Wang1, Yongsheng Wang1, Jiong Wu1, Peng Yuan1, Pin Zhang1, Qingyuan Zhang1, Hong Zheng1, Da Pang1, Guosheng Ren1, Zhimin Shao1, Zhenzhou Shen1, Erwei Song1, Santai Song1.   

Abstract

The recently available guidelines on the management of advanced breast cancer (ABC) organized by Chinese Anti-Cancer Association, Committee of Breast Cancer Society (CACA-CBCS) do not elucidate ABC in details. To instruct clinicians in treatment of ABC, a Chinese expert consensus meeting on diagnosis and treatment of ABC was held in June 2014 and a consensus is developed. The following consensus provides the level of evidence and supporting documents for each recommendation, and introduces research topics to be urgently addressed. Notably, the consensus on diagnosis and treatment of ABC in China is developed to be applied nationwide. In different areas, multidisciplinary treatment (MDT) tailored to the each patient and the disease itself should be applied based on the basic principles of modern oncology.

Entities:  

Keywords:  Advanced breast cancer (ABC); China; consensus; national

Year:  2015        PMID: 26605288      PMCID: PMC4620095          DOI: 10.3978/j.issn.2305-5839.2015.09.47

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  90 in total

1.  Imaging of metastatic breast cancer: distribution and radiological assessment at presentation.

Authors:  J P Whitlock; A J Evans; L Jackson; S Y Chan; J F Robertson
Journal:  Clin Oncol (R Coll Radiol)       Date:  2001       Impact factor: 4.126

2.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

3.  Leuprolide acetate plus aromatase inhibition for male breast cancer.

Authors:  Sharon H Giordano; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2006-07-20       Impact factor: 44.544

4.  Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.

Authors:  S Wang; M H Saboorian; E Frenkel; L Hynan; S T Gokaslan; R Ashfaq
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

5.  Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.

Authors:  Michael Andersson; Elisabeth Lidbrink; Karsten Bjerre; Erik Wist; Kristin Enevoldsen; Anders B Jensen; Per Karlsson; Ulla B Tange; Peter G Sørensen; Susanne Møller; Jonas Bergh; Sven T Langkjer
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

6.  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Authors:  Martin R Stockler; Vernon J Harvey; Prudence A Francis; Michael J Byrne; Stephen P Ackland; Bernie Fitzharris; Guy Van Hazel; Nicholas R C Wilcken; Peter S Grimison; Anna K Nowak; M Corona Gainford; Akiko Fong; Lisa Paksec; Tatiana Sourjina; Diana Zannino; Val Gebski; R John Simes; John F Forbes; Alan S Coates
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

7.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

8.  Use of reoperative sentinel lymph node biopsy in breast cancer patients.

Authors:  Charles E Cox; Ben T Furman; John V Kiluk; Julia Jara; William Koeppel; Tammi Meade; Laura White; Elisabeth Dupont; Nathon Allred; Michael Meyers
Journal:  J Am Coll Surg       Date:  2008-07       Impact factor: 6.113

Review 9.  Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis.

Authors:  Colleen M Costelloe; Eric M Rohren; John E Madewell; Tsuyoshi Hamaoka; Richard L Theriault; Tse-Kuan Yu; Valerae O Lewis; Jingfei Ma; R Jason Stafford; Ana M Tari; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Lancet Oncol       Date:  2009-06       Impact factor: 41.316

10.  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.

Authors:  Lee S Rosen; David H Gordon; William Dugan; Pierre Major; Peter D Eisenberg; Louise Provencher; Mary Kaminski; Joe Simeone; John Seaman; Bee-Lian Chen; Robert E Coleman
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

View more
  13 in total

Review 1.  Is internal mammary nodes irradiation as a part of breast cancer postoperative radiotherapy necessary?

Authors:  Zhi-Rui Zhou; Zhao-Zhi Yang; Xiao-Li Yu; Xiao-Mao Guo
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 2.  Phyllodes tumors of the breast: diagnosis, treatment and prognostic factors related to recurrence.

Authors:  Zhi-Rui Zhou; Chen-Chen Wang; Zhao-Zhi Yang; Xiao-Li Yu; Xiao-Mao Guo
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

3.  A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.

Authors:  Fei Xu; Qiufan Zheng; Wen Xia; Quchang Ouyang; Danmei Pang; Zhongyu Yuan; Yanxia Shi; Roujun Peng; Qianyi Lu; Shusen Wang
Journal:  Oncologist       Date:  2020-12-08

4.  A Case of Phyllodes Tumor of the Breast with Mixed Liposarcoma: Case Report and Literature Review.

Authors:  Mei Er Tu He Ta Mi Shi; Ning Wang; Qing Yao; Shuang-Shuang Dong; Xiao Feng; Jin Zhao; Hong Zou; Li-Juan Pang; Yan Qi
Journal:  Onco Targets Ther       Date:  2021-05-06       Impact factor: 4.147

5.  Ruanjian Sanjie decoction exhibits antitumor activity by inducing cell apoptosis in breast cancer.

Authors:  Xiumei Zhao; Jing Zhao; Renjie Hu; Qiang Yao; Guixian Zhang; Hongsheng Shen; Ernesto Yagüe; Yunhui Hu
Journal:  Oncol Lett       Date:  2017-03-08       Impact factor: 2.967

6.  Dosimetric factors and Lyman normal-tissue complication modelling analysis for predicting radiation-induced lung injury in postoperative breast cancer radiotherapy: a prospective study.

Authors:  Zhi-Rui Zhou; Qing Han; Shi-Xiong Liang; Xiao-Dong He; Nu-Yun Cao; Ying-Jie Zi
Journal:  Oncotarget       Date:  2017-05-16

7.  Salivary Glycopatterns as Potential Biomarkers for Screening of Early-Stage Breast Cancer.

Authors:  Xiawei Liu; Hanjie Yu; Yan Qiao; Jiajun Yang; Jian Shu; Jiaxu Zhang; Zhiwei Zhang; Jianjun He; Zheng Li
Journal:  EBioMedicine       Date:  2018-02-02       Impact factor: 8.143

8.  Yanghe Huayan decoction inhibits the capability of trans-endothelium and angiogenesis of HER2+ breast cancer via pAkt signaling.

Authors:  Xiao-Fei Liu; Jing-Wei Li; Hong-Zhi Chen; Zi-Yuan Sun; Guang-Xi Shi; Jian-Min Zhu; Ai-Li Song; Ying Wang; Xiang-Qi Li
Journal:  Biosci Rep       Date:  2019-02-15       Impact factor: 3.840

Review 9.  Shared decision making in breast cancer treatment guidelines: Development of a quality assessment tool and a systematic review.

Authors:  Marta Maes-Carballo; Isabel Muñoz-Núñez; Manuel Martín-Díaz; Luciano Mignini; Aurora Bueno-Cavanillas; Khalid Saeed Khan
Journal:  Health Expect       Date:  2020-08-03       Impact factor: 3.377

10.  A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy.

Authors:  Dongmei Ji; Weina Shen; Jian Zhang; Junning Cao; Wenhua Li; Lisa H Lam; Fan Wu; Bei Wang; Zao Li; Guofang Sun; Xichun Hu; Shang-Chiung Chen
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.